Financial Avengers Inc. Acquires 24,642 Shares of Pfizer Inc. (NYSE:PFE)

Financial Avengers Inc. increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 88.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,584 shares of the biopharmaceutical company's stock after purchasing an additional 24,642 shares during the period. Pfizer makes up 0.7% of Financial Avengers Inc.'s investment portfolio, making the stock its 23rd biggest holding. Financial Avengers Inc.'s holdings in Pfizer were worth $1,395,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Focus Partners Advisor Solutions LLC grew its holdings in Pfizer by 20.9% in the 4th quarter. Focus Partners Advisor Solutions LLC now owns 124,346 shares of the biopharmaceutical company's stock valued at $3,299,000 after buying an additional 21,519 shares during the last quarter. Ames National Corp acquired a new stake in shares of Pfizer in the fourth quarter worth $429,000. Glen Eagle Advisors LLC raised its stake in Pfizer by 24.1% during the 4th quarter. Glen Eagle Advisors LLC now owns 29,862 shares of the biopharmaceutical company's stock valued at $792,000 after purchasing an additional 5,796 shares during the last quarter. White Knight Strategic Wealth Advisors LLC boosted its holdings in Pfizer by 50.5% in the 4th quarter. White Knight Strategic Wealth Advisors LLC now owns 23,154 shares of the biopharmaceutical company's stock valued at $614,000 after purchasing an additional 7,772 shares during the period. Finally, Mpwm Advisory Solutions LLC acquired a new stake in Pfizer in the 4th quarter worth $154,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE stock opened at $23.51 on Wednesday. The company has a market capitalization of $133.66 billion, a P/E ratio of 16.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company's 50 day moving average price is $23.56 and its two-hundred day moving average price is $25.27.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the prior year, the firm earned $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.32%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is presently 124.64%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.